

Original articles in peer reviewed journals

2011 (In Press)

Reich K, Schenkel B, Zhao N, Szapary P, Augustin M, Bourcier M, Guenther L, Langley RG. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2. *J Dermatolog Treat.* 2010 Oct 31. [Epub in Medline ahead of print]

2011

Augustin M, Schäfer I, **Reich K**, Glaeske G, Radtke M. Systemic treatment with corticosteroids in psoriasis-health care provision far beyond the S3-guidelines. *J Dtsch Dermatol Ges.* 2011; 9(10):833-8.

Dirschka T, **Reich K**, Bissonnette R, Maares J, Brown T, Diepgen TL. An open-label study assessing the safety and efficacy of alitretinoin in patients with severe chronic hand eczema unresponsive to topical corticosteroids. *Clin Exp Dermatol.* 2011;36(2):149-54.

Franzke N, Schäfer I, Jost K, Blome C, Rustenbach SJ, **Reich K**, Reusch M, Maurer M, Augustin M. A new instrument for the assessment of patient-defined benefit in the treatment of allergic rhinitis. *Allergy.* 2011;66(5):665-70.

Häfner D, **Reich K**, Matricardi PM, Meyer H, Kettner J, Narkus A. Prospective validation of 'Allergy-Control-SCORE(TM)': a novel symptom-medication score for clinical trials. *Allergy.* 2011;66(5):629-36.

Kahl C, Neureither M, **Reich K**, Zschocke I. Time management and quality of life after change of therapy from topical treatment and/or phototherapy to Fumaderm® in patients with psoriasis. *Akt Dermatol.* 2011;37(7):249-53.

Kasperkiewicz M, Schmidt E, Frambach Y, Rose C, Meier M, Nitschke M, Falk TM, **Reich K**, Ludwig RJ, Zillikens D. Improvement of treatment-refractory atopic dermatitis by immunoabsorption: A pilot study. *J Allergy Clin Immunol.* 2011;127(1):267-70.

Leonardi C, Papp K, Strober B, **Reich K**, Asahina A, Gu Y, Beason J, Rozzo S, Tying S. The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. *Am J Clin Dermatol.* 2011;12(5):321-37.

Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried S, Brehler R, Grabbe J, Hunzelmann N, Jakob T, Jung A, Kleine-Tebbe J, Mempel M, Meurer M, **Reich K**, Ruëff F, Schäkel K, Sengupta K, Sieder C, Simon JC, Wedi B, Zuberbier T, Mahler V, Staubach P. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. *J Allergy Clin Immunol.* 2011;128(1):202-9.

Mrowietz U, Adamczyk A, Augustin M, Boehncke WH, Bonnekoh B, Gambichler T, Hengge U, Lippert U, Ludwig RJ, Luger T, Merk HF, Norgauer J, Philipp S, **Reich K**, Röcken M, Rostami-Yazdi M, Schön MP, Scola N, Sticherling M, Thaci D, Viehweg A, Wallbrecht K, Wozel G, Zouboulis CC, Neureither M. Neue Erkenntnisse zu Fumarsäureestern (Fumaderm®): Ergebnisse eines Experten-Workshops. *J Dtsch Dermatol Ges.* 2011;9 (Suppl 4):1-13.

Mrowietz U, Kragballe K, **Reich K**, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Daudén E, Gisondi P, Iversen L, Kemény L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N. Definition of treatment goals for moderate to severe psoriasis: a European consensus. *Arch Dermatol Res.* 2011 ;303(1):1-10.

Ortonne JP, Chimenti S, **Reich K**, Gniadecki R, Sprøgel P, Unnebrink K, Kupper H, Goldblum O, Thaçi D. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. *J Eur Acad Dermatol Venereol.* 2011;25(9):1012-1020.

Ortonne JP, Nikkels AF, **Reich K**, Ponce Olivera RM, Lee JH, Kerrouche N, Sidou F, Faergemann J. Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0.05% combined with ketoconazole shampoo 2%: a randomized, controlled study. *Br J Dermatol.* 2011;165(1):171-6.

Radtke MA, Langenbruch AK, Schäfer I, Herberger K, **Reich K**, Augustin M. Nail psoriasis as a severity indicator: results from the PsoReal study. *Patient Related Outcome Measures.* 2011;2:1-6.

Reich K, Gessner C, Kroker A, Schwab JA, Pohl W, Villesen H, Wüstenberg E, Emminger W. Immunologic Effects and Tolerability Profile of In-Season Initiation of a Standardized-Quality Grass Allergy Immunotherapy Tablet: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial in Adults with Grass Pollen-Induced Rhinoconjunctivitis. *Clin Ther.* 2011;33(7):828-40.

Reich K, Langley RG, Lebwohl M, Szapary P, Guzzo C, Yeilding N, Li S, Hsu MC, Griffiths CE. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. *Br J Dermatol.* 2011;164(4):862-72.

Saurat JH, Langley RG, **Reich K**, Unnebrink K, Sasso EH, Kampman W. Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study. *Br J Dermatol.* 2011;165(2):399-406.

2010

Augustin M, Glaeske G, Radtke MA, Christophers E, **Reich K**, Schäfer I. Epidemiology and comorbidity of psoriasis in children. *Br J Dermatol.* 2010;162(3):633-6.

Augustin M, **Reich K**, Blome C, Schäfer I, Laass A, Radtke MA. Nail psoriasis in Germany: epidemiology and burden of disease. *Br J Dermatol.* 2010;163(3):580-5.

Augustin M, **Reich K**, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. *Acta Derm Venereol.* 2010;90(2):147-51.

Avouac J, Walker U, Tyndall A, Kahan A, Matucci-Cerinic M, Allanore Y; EUSTAR, Miniati I, Muller A, Iannone F, Distler O, Becvar R, Sierakowsky S, Kowal-Bielecka O, Coelho P, Cabane J, Cutolo M, Shoenfeld Y, Valentini G, Rovensky J, Riemekasten G, Vlachoyiannopoulos P, Caporali R, Jiri S, Inanc M, Zimmermann Gorska I, Carreira P, Novak S, Czirjak L, Oliveira Ramos F, Jendro M, Chizzolini C, Kucharz EJ, Richter J, Cozzi F, Rozman B, Mallia CM, Gabrielli A, Farge D, Kiener HP, Schöffel D, Airo P, Wollheim F, Martinovic D, Trotta F, Jablonska S, **Reich K**, et al. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. *J Rheumatol.* 2010;37(7):1488-501.

Hüffmeier U, Bergboer JG, Becker T, Armour JA, Traupe H, Estivill X, Riveira-Munoz E, Mössner R, **Reich K**, Kurrat W, Wienker TF, Schalkwijk J, Zeeuwen PL, Reis A. Replication of LCE3C-LCE3B CNV as a risk factor for psoriasis and analysis of interaction with other genetic risk factors. *J Invest Dermatol.* 2010;130(4):979-84.

Kingo K, Mössner R, Traks T, Rätsep R, Raud K, Reimann E, Krüger U, Silm H, Vasar E, **Reich K**, Kõks S. Further association analysis of chr 6q22-24 suggests a role of IL-20RA polymorphisms in psoriasis. *J Dermatol Sci.* 2010;57(1):71-3.

Lebwohl M, Yeilding N, Szapary P, Wang Y, Li S, Zhu Y, **Reich K**, Langley RG, Papp KA. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations. *J Am Acad Dermatol.* 2010;63(4):571-9.

Radtke MA, Augustin J, Blome C, **Reich K**, Rustenbach SJ, Schäfer I, Laass A, Augustin M. How do regional factors influence psoriasis patient care in Germany? *J Deutsch Ges Dermatol*. 2010;8(7):516-24.

Reich K, Ortonne JP, Kerkmann U, Wang Y, Saurat JH, Papp K, Langley R, Griffiths CE. Skin and Nail Responses after 1 Year of Infliximab Therapy in Patients with Moderate-to-Severe Psoriasis: A Retrospective Analysis of the EXPRESS Trial. *Dermatology*. 2010;221(2):172-8.

Reich K, Shakery K, Mrowietz U, Szapary PO, Wang Y, Hsu M-C, Langley RG. Ustekinumab and marked clinical responses in patients with moderate to severe psoriasis. *Psoriasis Forum*. 2010;16(1):3-11.

Reich K, Signorovitch J, Ramakrishnan K, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM. Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial. *J Am Acad Dermatol*. 2010;63(6):1011-8.

Szeimies RM, Radny P, Sebastian M, Borrosch F, Dirschka T, Krähn-Senftleben G, **Reich K**, Pabst G, Voss D, Foguet M, Gahlmann R, Lübbert H, Reinhold U. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. *Br J Dermatol*. 2010;163(2):386-94.

Szeimies RM, Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R, Mensing H, Reinhold U, **Reich K**, Moor AC, Stocker M, Ortland C, Brunnert M, Hauschild A. Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data. *Br J Dermatol*. 2010;162(2):410-4.

2009

Augustin M, **Reich K**, Reusch M, Luger T, Franzke N, Schäfer I, Rustenbach SJ, Radtke MA. Health services research in psoriasis - The german approach. *Dermatology*. 2009;218(4):293-301.

Chang YM, Newton-Bishop JA, Bishop DT, Armstrong BK, Bataille V, Bergman W, Berwick M, Bracci PM, Elwood JM, Ernstoff MS, Green AC, Gruis NA, Holly EA, Ingvar C, Kanetsky PA, Karagas MR, Marchand LL, Mackie RM, Olsson H, Osterlind A, Rebbeck TR, **Reich K**, Sasieni P, Siskind V, Swerdlow AJ, Titus-Ernstoff L, Zens MS, Ziegler A, Barrett JH. A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. *Int J Cancer*. 2009;124(2):420-8.

Hanitsch LG, Burmester GR, Witt C, Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, Müller-Ladner U, Schulze-Lohoff E, Becker M, Sunderkoetter C; DNSS centers, Riemekasten G. Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Rheumatology (Oxford). 2009;48(1):70-3. [Prof. Reich is a DNSS center]

Hauschild A, Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R, Mensing H, Reinhold U, **Reich K**, Moor AC, Stocker M, Ortland C, Brunnert M, Szeimies RM. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. *Br J Dermatol*. 2009;160(5):1066-74.

Hüffmeier U, Lascorz J, Becker T, Schürmeier-Horst F, Magener A, Ekici AB, Ende S, Thiel CT, Thoma-Uszynski S, Mössner R, **Reich K**, Kurrat W, Wienker TF, Traupe H, Reis A. Characterization of psoriasis susceptibility locus 6 (PSORS6) in patients with early onset psoriasis and evidence for interaction with PSORS1. *J Med Genet*. 2009;46(11):736-44.

Hüffmeier U, Lascorz J, Böhm B, Lohmann J, Wendler J, Mössner R, **Reich K**, Traupe H, Kurrat W, Burkhardt H, Reis A. Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. *J Invest Dermatol*. 2009;129(2):355-8.

Mease PJ, **Reich K**. Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. *J Am Acad Dermatol*. 2009;60(3):402-11.

Mössner R, Stiens G, König IR, Schmidt D, Platzer A, Krüger U, **Reich K**. Analysis of a functional serotonin transporter promoter polymorphism in psoriasis vulgaris. *Arch Dermatol Res*. 2009;301(6):443-7.

Müller-Ladner U, Alten R, Heiligenhaus A, Kekow J, Koletzko S, Mrowietz U, Ochsenkühn T, Radke M, **Reich K**, Rudwaleit M, Schreiber S. ["TRECID", TNFalpha related chronic inflammatory diseases - a new multiple diseases bridging concept]. *Dtsch Med Wochenschr*. 2009;134(42):2132-6.

Radtke MA, **Reich K**, Blome C, Kopp I, Rustenbach SJ, Schäfer I, Augustin M. Evaluation of Quality of Care and Guideline-Compliant Treatment in Psoriasis. Development of a New System of Quality Indicators. *Dermatology*. 2009;219(1):54-8.

Radtke M, **Reich K**, Blome C, Rustenbach S, Augustin M. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. *J Eur Acad Dermatol Venereol*. 2009;23(6):683-91.

Reich K. Wirksamkeit und Sicherheit des humanen monoklonalen Interleukin-12/23-Antikörpers Ustekinumab bei Patienten mit Psoriasis: Ergebnisse der randomisierten, doppel-blinden, plazebokontrollierten Phase-III-Studien PHOENIX 1 und PHOENIX 2. *Akt Dermatol*. 2009;35(1/2):29-34.

Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. *Br J Dermatol.* 2009;160(5):1040-7.

Reich K, Segaert S, Van de Kerkhof P, Durian C, Boussuge MP, Paolozzi L, Wajdula J, Boggs R. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. *Dermatology.* 2009;219(3):239-49.

Reich K, Thaci D, Mrowietz U, Kamps A, Neureither M, Luger T. Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis--a retrospective study (FUTURE). *J Dtsch Dermatol Ges.* 2009;7(7):603-11.

Schoof N, von Bonin F, König IR, Mössner R, Krüger U, **Reich K**, Berking C, Volkenandt M, Ziegler A, Böckmann L, Kuschal C, Thoms KM, Kube D, Emmert S. Distal and proximal interleukin (IL)-10 promoter polymorphisms associated with risk of cutaneous melanoma development: a case--control study. *Genes Immun.* 2009;10(6):586-90.

Schnuch A, Szliska C, Uter W; IVDK. [Facial allergic contact dermatitis. Data from the IVDK and review of literature]. *Hautarzt.* 2009;60(1):13-21. [Prof. Reich is a member of the IVDK]

Sunderkötter C, Herrgott I, Brückner C, Moinzadeh P, Pfeiffer C, Gerss J, Hunzelmann N, Böhm M, Krieg T, Müller-Ladner U, Genth E, Schulze-Lohoff E, Meurer M, Melchers I, Riemekasten G; DNSS Centers. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. *Br J Dermatol.* 2009;160(4):835-43. [Prof. Reich was one of the collaborators]

van de Kerkhof PC, Hoffmann V, Anstey A, Barnes L, Bolduc C, **Reich K**, Saari S, Segaert S, Vaillant L. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. *Br J Dermatol.* 2009;160(1):170-6.

Zschocke I, Lotzin A, Sebastian M, Dirschka T, Zielke A, **Reich K**. Wirksamkeit einer kombinierten Therapie der atopischen Dermatitis mit Triclosan und Flumetasinpivalat (DuoGalen®Creme). *Akt Dermatol.* 2009;35(12):496-501.

2008

Augustin M, Krüger K, Radtke MA, Schwippel I, **Reich K**. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. *Dermatology.* 2008;216(4):366-72.

Augustin M, **Reich K**, Reich C, Purwins S, Jeff Rustenbach S, Schäfer I, Radtke M. Quality of psoriasis care in Germany - results of the national study PsoHealth 2007. *J Dtsch Dermatol Ges.* 2008;6(8):640-5.

Haenssle H, Buhl T, Knudsen S, Krueger U, Rosenberger A, **Reich K**, Neumann C. CD40 ligation during dendritic cell maturation reduces cell death and prevents interleukin-10-induced regression to macrophage-like monocytes. *Exp Dermatol*. 2008;17(3):177-87.

Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, Moinzadeh P, Müller-Ladner U, Pfeiffer C, Riemekasten G, Schulze-Lohoff E, Sunderkoetter C, Weber M, Worm M, Klaus P, Rubbert A, Steinbrink K, Grundt B, Hein R, Scharffetter-Kochanek K, Hinrichs R, Walker K, Szeimies RM, Karrer S, Müller A, Seitz C, Schmidt E, Lehmann P, Foeldvári I, Reichenberger F, Gross WL, Kuhn A, Haust M, **Reich K**, Böhm M, Saar P, Fierlbeck G, Kötter I, Lorenz HM, Blank N, Gräfenstein K, Juche A, Aberer E, Bali G, Fiehn C, Stadler R, Bartels V; Registry of the German Network for Systemic Scleroderma. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. *Rheumatology (Oxford)*. 2008; 47(8):1185-92.

Kingo K, Mössner R, Rätsep R, Raud K, Krüger U, Silm H, Vasar E, **Reich K**, Kõks S. Association analysis of IL20RA and IL20RB genes in psoriasis. *Genes Immun*. 2008;9(5):445-51.

Menter A, **Reich K**, Gottlieb AB, Bala M, Li S, Hsu MC, Guzzo C, Diels J, Gelfand JM. Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations. *J Drugs Dermatol*. 2008; 7(12):1137-46.

Mössner R, Thaci D, Mohr J, Pätzold S, Bertsch HP, Krüger U, **Reich K**. Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases. *Arch Dermatol Res*. 2008;300(3):101-5.

Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, **Reich K**; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). *Lancet*. 2008 ;371(9625):1675-84.

Reich K, Griffiths CE. The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. *Arch Dermatol Res*. 2008; 300(10):537-44.

Reich K, Griffiths CE, Barker J, Chimenti S, Daudén E, Gianetti A, Gniadecki R, Katsambas A, Langley R, Mrowietz U, Ogilvie A, Ortonne JP, Reider N, Saurat JH. Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus. *Dermatology*. 2008;217(3):268-75.

Reich K, Sinclair R, Roberts G, Griffiths CE, Tabberer M, Barker J. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis. *Curr Med Res Opin.* 2008; 24(5):1237-54.

Rich P, Griffiths CEM, **Reich K**, Nestle FO, Scher RK, Li S, Xu S, Hsu MC, Guzzo C. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. *J Am Acad Dermatol.* 2008;58(2):224-31.

Zschocke I, Reich C, Zielke A, Reitmeier N, **Reich K**. Silica gel is as effective as acyclovir cream in patients with recurrent herpes labialis: results of a randomized, open-label trial. *J Dermatolog Treat.* 2008;19(3):176-81.

2007

Kingo K, Mössner R, Köks S, Rätsep R, Krüger U, Vasar E, **Reich K**, Silm H. Association analysis of IL19, IL20 and IL24 genes in palmoplantar pustulosis. *Br J Dermatol.* 2007;156(4):646-52.

Mössner R, Anders N, König IR, Krüger U, Schmidt D, Berking C, Ziegler A, Brockmüller J, Kaiser R, Volkenandt M, Westphal GA, **Reich K**. Variations of the melanocortin-1 receptor and the glutathione-S transferase T1 and M1 genes in cutaneous malignant melanoma. *Arch Dermatol Res.* 2007;298(8):371-9.

Mössner R, Meyer P, Jankowski F, König IR, Krüger U, Kammerer S, Westphal G, Boettger MB, Berking C, Schmitt C, Brockmüller J, Ziegler A, Stapelmann H, Kaiser R, Volkenandt M, **Reich K**. Variations in the peroxisome proliferator-activated receptor-gamma gene and melanoma risk. *Cancer Lett.* 2007;246(1-2):218-23.

Niedermeier A, Eming R, Pfützte M, Neumann CR, Happel C, **Reich K**, Hertl M. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). *Arch Dermatol.* 2007;143(2):192-8.

Reich K, Huffmeier U, König IR, Lascorz J, Lohmann J, Wendler J, Traupe H, Mössner R, Reis A, Burkhardt H. TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele. *Arthritis Rheum.* 2007;56(6):2056-2064.

Reich K, Menter A, Plotnick M, Guzzo C, Li S, Gottlieb A. Consistency of Infliximab response across subgroups of patients with psoriasis. Integrated results from randomized clinical trials. *Psoriasis Forum.* 2007; 13:21-7.

Reich K, Nestle FO, Wu Y, Bala M, Eisenberg D, Guzzo C, Li S, Dooley LT, Griffiths CE. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. *Eur J Dermatol.* 2007;17(5):381-6.

Schöffski O, Augustin M, Prinz J, Rauner K, Schubert E, Sohn S, **Reich K**. Krankheitskosten und Lebensqualität bei Patienten mit mittelschwerer bis schwerer Psoriasis vulgaris in Deutschland: eine multizentrische Studie. *J Dtsch Dermatol Ges*. 2007;5(3):209-19.

2006

Huffmeier U, Steffens M, Burkhardt H, Lascorz J, Schurmeier-Horst F, Stander M, Kelsch R, Baumann C, Kuster W, Mössner R, **Reich K**, Wienker TF, Traupe H, Reis A. Evidence for susceptibility determinant(s) to psoriasis vulgaris in or near PTPN22 in German patients. *J Med Genet*. 2006;43(6):517-22.

Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo CA, Li S, Dooley LT, Griffiths CE. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate- to-severe psoriasis: a randomized controlled trial. *Br J Dermatol*. 2006;154(6):1161-8.

Sohn S, Schoeffski O, Prinz J, **Reich K**, Schubert E, Waldorf K, Augustin M. Cost of moderate-to-severe plaque-psoriasis in Germany: a multicentre cost-of-illness study. *Dermatology*. 2006;212(2):137-44.

2005

Blankenburg S, König IR, Mössner R, Laspe P, Thoms KM, Krüger U, Khan SG, Westphal G, Berking C, Volkenandt M, **Reich K**, Neumann C, Ziegler A, Kraemer KH, Emmert S. Assessment of 3 xeroderma pigmentosum group C gene polymorphisms and risk of cutaneous melanoma: a case-control study. *Carcinogenesis*. 2005;26(6):1085-90.

Blankenburg S, König IR, Mössner R, Laspe P, Thoms KM, Krüger U, Khan SG, Westphal G, Volkenandt M, Neumann C, Ziegler A, Kraemer KH, **Reich K**, Emmert S. No association between three xeroderma pigmentosum group C and one group G gene polymorphisms and risk of cutaneous melanoma. *Eur J Hum Genet*. 2005;13(2):253-5.

Distler JH, Jungel A, Kowal-Bielecka O, Michel BA, Gay RE, Sprott H, Matucci-Cerinic M, Chilla M, **Reich K**, Kalden JR, Muller-Ladner U, Lorenz HM, Gay S, Distler O. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. *Arthritis Rheum*. 2005;52(3):856-64.

Mössner R, Kingo K, Kleinsang A, Krüger U, König IR, Silm H, Westphal GA, **Reich K**. Association of TNF -238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris. *J Invest Dermatol*. 2005;124(1):282-4.

Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. *Lancet*. 2005;366(9494):1367-74.

2004

Mössner R, Beckmann I, Hallermann C, Neumann C, **Reich K**. Granulocyte colony-stimulating-factor-induced psoriasiform dermatitis resembles psoriasis with regard to abnormal cytokine expression and epidermal activation. *Exp Dermatol*. 2004;13(6):340-6.

Mössner R, Kaiser R, Matern P, Kruger U, Westphal GA, Brockmöller J, Ziegler A, Neumann C, König IR, **Reich K**. Variations in the genes encoding the peroxisome proliferator-activated receptors alpha and gamma in psoriasis. *Arch Dermatol Res*. 2004;296(1):1-5.

Mössner R, Tings T, Beckmann I, Neumann C, Paulus W, **Reich K**. A close look at autoimmune muscle disorders: association of Lambert-Eaton myasthenic syndrome with dermatomyositis. *Scand J Rheumatol*. 2004;33(4):271-5.

Reich K, Hugo S, Middel P, Blaschke V, Heine A, Neumann C. The maturation-dependent production of interleukin-16 is impaired in monocyte-derived dendritic cells from atopic dermatitis patients but is restored by inflammatory cytokines TNF-alpha and IL-1beta. *Exp Dermatol*. 2004;13(12):740-7.

2003

Blaschke S, Middel P, Dorner BG, Blaschke V, Hummel KM, Kroczeck RA, **Reich K**, Benoehr P, Koziol M, Müller GA. Expression of activation-induced, T cell-derived, and chemokine-related cytokine/lymphotactin and its functional role in rheumatoid arthritis. *Arthritis Rheum*. 2003;48(7):1858-72.

Reich K, Westphal GA, König IR, Mössner R, Krüger U, Ziegler A, Neumann C, Schnuch A. Association of allergic contact dermatitis with a promoter polymorphism in the IL16 gene. *J Allergy Clin Immunol*. 2003;112(6):1191-4.

Reich K, Westphal GA, König IR, Mössner R, Schupp P, Gutgesell C, Hallier E, Ziegler A, Neumann Ch. Cytokine gene polymorphisms in atopic dermatitis. *Br J Dermatol*. 2003;148(6):1237-41.

Westphal GA, Schnuch A, Mössner R, König IR, Kränke B, Hallier E, Ziegler A, **Reich K**. Cytokine gene polymorphisms in allergic contact dermatitis. *Contact Dermatitis*. 2003;48(2):93-8.

2002

Blaschke V, **Reich K**, Blaschke S, Zipprich S, Neumann C. Quantitative RT-PCR: comparing real-time lightcycler technology with quantitative competitive RT-PCR. *Biochemica*. 2002;(1):6-8.

Mössner R, Schulz U, Krüger U, Middel P, Schinner S, László Fuzesi L, Neumann C, **Reich K**. Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma. *J Invest Dermatol*. 2002;119(3):576-82.

Reich K, Hugo S, Middel P, Blaschke V, Heine A, Gutgesell C, Williams R, Neumann Ch. Evidence for a role of Langerhans cell-derived interleukin-16 in atopic dermatitis. *J Allergy Clin Immunol*. 2002;109(4):681-7.

Reich K, Mössner R, König IR, Westphal G, Ziegler A, Neumann Ch. Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset. *J Invest Dermatol*. 2002;118(1):155-63.

2001

Gräfe A, Vente C, **Reich K**, Hallermann Ch, Neumann Ch. Wegenersche Granulomatose unter dem klinischen Bild einer Vasculitis allergica. *Akt Dermatol*. 2001;27(10):323-7.

Middel P, **Reich K**, Polzien F, Blaschke V, Hemmerlein B, Herms J, Korabiowska M, Radzun HJ. Interleukin-16 expression and phenotype of interleukin-16 producing cells in Crohn's disease. *Gut*. 2001;49(6):795-803.

Middel P, Thelen P, Blaschke S, Polzien F, **Reich K**, Blaschke V, Wrede A, Hummel KM, Gunawan B, Radzun HJ. Expression of the T-cell chemoattractant chemokine lymphotactin in Crohn's disease. *Am J Pathol*. 2001;159(5):1751-61.

Reich K, Garbe C, Blaschke V, Maurer C, Middel P, Westphal G, Lippert U, Neumann Ch. Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal IL-8/CXCR2 pathway and normalization of keratinocyte maturation. *J Invest Dermatol*. 2001;116(2):319-29.

Reich K, Heine A, Hugo S, Blaschke V, Middel P, Kaser A, Tilg H, Blaschke S, Gutgesell C, Neumann Ch. Engagement of the high affinity IgE receptor, FcεRI, stimulates the production of IL-16 in Langerhans cell-like dendritic cells. *J Immunol*. 2001;167(11):6321-9.

2000

Blaschke V, **Reich K**, Blaschke S, Zipprich S, Neumann Ch. Rapid quantitation of proinflammatory and chemoattractant cytokine expression in small tissue samples and monocyte-derived dendritic cells, Validation of a new real-time RT-PCR technology. *J Immunol Methods*. 2000;246(1-2):79-90.

Westphal GA, **Reich K**, Schulz TG, Neumann Ch, Hallier E, Schnuch A. N-acetyltransferases 1 and 2 polymorphisms in para-substituted arylamine-induced contact allergy. *Br J Dermatol*. 2000;142(6):1121-7.

Westphal GA, Schnuch A, Schulz TG, **Reich K**, Aberer W, Brasch J, Koch P, Wessbecher R, Szliska C, Bauer A, Hallier E. Homozygous gene deletions of the glutathione S-transferases M1 and T1 are associated with thimerosal sensitization. *Int Arch Occup Environ Health*. 2000;73(6):384-8.

1999

Blaschke V, **Reich K**, Middel P, Letschert M, Sachse F, Harwix S, Neumann Ch. Expression of the CD4+ cell-specific chemoattractant interleukin-16 in mycosis fungoides. *J Invest Dermatol*. 1999;113(4):658-63.

Reich K, Brinck U, Letschert M, Blaschke V, Dames K, Braess J, Wörmann B, Rüniger TM, Neumann Ch. Graft-versus-host disease-like cutaneous immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigus. *Br J Dermatol*. 1999;141(4):739-46 .

Reich K, Westphal GA, Schulz TG, Müller M, Zipprich S, Fuchs Th, Hallier E, Neumann Ch. Combined analysis of polymorphisms of the tumor necrosis factor-alpha and interleukin-10 promoter regions and polymorphic xenobiotic metabolizing enzymes in psoriasis. *J Invest Dermatol*. 1999;113(2):214-20.

Vente C, **Reich K**, Rupprecht R, Neumann Ch. Erosive mucosal lichen planus, response to topical treatment with tacrolimus. *Br J Dermatol*. 1999;140(2):338-42.

1998

Schnuch A, Westphal GA, Müller MM, Schulz TG, Geier J, Brasch J, Merk HF, Kawakubo Y, Richter G, Koch P, Fuchs Th, Gutgesell C, **Reich K**, Gebhardt M, Becker D, Grabbe J, Sziska C, Aberer W, Hallier E. Genotype and phenotype of N-acetyltransferase 2 (NAT2): polymorphism in patients with contact allergy. *Contact Dermatitis*. 1998;38(4):209-11.

1997

Boxberger HJ, Meyer TF, Grausam MC, **Reich K**, Becker HD, Sessler MJ. Isolating and maintaining highly polarized primary epithelial cells from normal human duodenum for growth as spheroid-like vesicles. *In Vitro Cell Dev Biol Anim*. 1997;35(7):536-45.

Braess J, **Reich K**, Willert S, Strutz F, Neumann Ch, Hiddemann W, Wörmann B. Mucocutaneous autoimmune syndrome following fludarabine therapy for low-grade non-Hodgkin's lymphoma of B-cell type (B-NHL). *Ann Hematol*. 1997;75(5-6):227-30.

1996

Seifarth C, Deusch K, **Reich K**, Classen M. Local cellular immune response in Helicobacter pylori associated type B-gastritis - selective increase of CD4+ but not gamma/delta T-cells in the immune response to H. pylori antigens. Z Gastroenterol. 1996;34(4):215-24.

1995

Reich K, Dähne I, Endres N, Classen M, Deusch K. Biased T-cell receptor V-beta repertoire of intestinal CD8+ T-cells in HIV-disease. Adv Exp Med Biol. 1995;371B:1023-6.

Seifarth C, Funk A, **Reich K**, Dähne I, Classen M, Deusch K. Selective increase of CD4+ and CD25+ T-cells but not of gamma/delta T-cells in H pylori associated gastritis. Adv Exp Med Biol. 1995;371B:931-4.

1992

Van-Kerckhove C, Russel GJ, Deusch K, **Reich K**, Bhan AK, DerSimonian H, Brenner MB. Oligoclonality of human intestinal intraepithelial T-cells. J Exp Med. 1992;175(1):57-63.

1991

Deusch K, Lüling F, **Reich K**, Classen M, Wagner H, Pfeffer K. A major fraction of human intraepithelial lymphocytes simultaneously expresses the gamma/delta T-cell receptor, the CD8 accessory molecule and preferentially uses the V-delta 1 gene segment. Eur J Immunol. 1991;21(4):1053-9.

Deusch K, Pfeffer K, **Reich K**, Gstettenbauer M, Daum S, Lüling F, Classen M. Phenotypic and functional characterization of human TCR gamma/delta+ intestinal intraepithelial lymphocytes. Curr Top Microbiol Immunol. 1991;173:279-83.

Reviews in peer reviewed journals

2011 (In Press)

Sticherling M, Augustin M, Boehncke WH, Christophers E, Domm S, Gollnick H, **Reich K**, Mrowietz U. Therapy of psoriasis in childhood and adolescence - a German expert consensus. *J Dtsch Dermatol Ges.* 2011 May 18. doi:10.1111/j.1610-0387.2011.07668.x. [Epub ahead of print]

2011

Langley R, **Reich K**. In touch with psoriasis: a patient-centred approach to therapy. *J Eur Acad Dermatol Venereol.* 2011;25 Suppl 4:1-2.

Mrowietz U, Kragballe K, Nast A, **Reich K**. Strategies for improving the quality of care in psoriasis with the use of treatment goals--a report on an implementation meeting. *J Eur Acad Dermatol Venereol.* 2011;25 Suppl 3:1-13.

Murphy G, **Reich K**. In touch with psoriasis: topical treatments and current guidelines. *J Eur Acad Dermatol Venereol.* 2011;25(Suppl 4):3-8.

Radtke MA, **Reich K**, Beikert F, Augustin M. Psoriasisarthritis: eine interdisziplinäre Herausforderung. *Hautarzt.* 2011;62(10):779-92.

Reich K, Bewley A. What is new in topical therapy for psoriasis? *J Eur Acad Dermatol Venereol.* 2011;25(Suppl 4):15-20.

Schnuch A, Westphal G, Mössner R, Uter W, **Reich K**. Genetic factors in contact allergy--review and future goals. *Contact Dermatitis.* 2011;64(1):2-23.

2010

Psoriasis: looking deeper into skin and nail diseases. Saurat JH, **Reich K**, editors. *Dermatology* 2010;221(Suppl1): 1-48.

2009

Mössner R, **Reich K**. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab. *Curr Probl Dermatol.* 2009;38:107-36.

Mrowietz U, **Reich K**. Psoriasis – neue Erkenntnisse zur Pathogenese und Therapie. *Dtsch Arztebl Int.* 2009;106(1-2):11-9.

Mrowietz U, Rostami-Yazdi M, Neureither M, **Reich K**. [15 years of fumaderm: fumaric acid esters for the systemic treatment of moderately severe and severe psoriasis vulgaris]. *J Dtsch Dermatol Ges.* 2009;7 Suppl 2:S3-16.

Reich K. Approach to managing patient with nail psoriasis. *JEADV.* 2009; 23(Suppl. 1):15-21.

Reich K. Ustekinumab for the treatment of plaque psoriasis. *Expert Rev Dermatol.* 2009;4(5):443-53.

Reich K, Yasothan U, Kirkpatrick P. Ustekinumab. *Nat Rev Drug Discov.* 2009;8(5):355-6.

Shakery K, Mrowietz U, **Reich K.** Psoriasis und das metabolische Syndrom: Viel mehr als eine Hautkrankheit. *Der Deutsche Dermatologe.* 2009;57(5):307-11.

2008

Finlay AY, **Reich K.** Outcome assessment and treatment goals. *Expert Rev Dermatol.* 2008; 3(4s):S39-S40.

Mössner R, Schön MP, **Reich K.** Tumor necrosis factor antagonists in the therapy of psoriasis. *Clin Dermatol.* 2008; 26(5):486-502.

Reich K. Keynote lecture: psoriasis update. *Expert Rev Dermatol.* 2008; 3(4s):S3-S9.

2007

Radtke MA, Mössner R, Augustin M, **Reich K.** Psoriasis-Arthritis. Therapeutische Strategien: je früher desto besser. *Der Deutsche Dermatologe.* 2007;55(6):1-4.

Radtke MA, Mössner R, Augustin M, **Reich K.** Psoriasis-Arthritis. Klinik, Pathogenese und Diagnostik. *Der Deutsche Dermatologe.* 2007;55(5):327-33.

Reich K, Mrowietz M. Treatment goals in psoriasis. *J Dtsch Dermatol Ges.* 2007;5(7):566-574.

Roll A, **Reich K,** Böer A. Use of fumaric acid esters in psoriasis. *Indian J Dermatol Venereol Leprol.* 2007;73(2):133-7.

2006

Boehncke WH, Friedrich M, Kaltwasser JP, Manger B, Mrowietz U, **Reich K,** Rosenbach T. Psoriasis-Arthritis: eine interdisziplinäre Herausforderung. *Dtsch Arztebl.* 2006;103(21):1455-61.

Distler M, Distler J, Ciurea A, Kyburz D, Müller-Ladner U, **Reich K,** Distler O. Evidenzbasierte Therapie des Raynaud-Syndroms. *Z Rheumatol.* 2006;65(4):285-9.

Mössner R, **Reich K.** Biologics in der Therapie der Psoriasis: unerwünschte Effekte an der Haut. *Allergo J.* 2006;15(7):492-500.

Mössner R, **Reich K.** Infliximab in the treatment of psoriasis. *Expert Rev Dermatol.* 2006;1(4):515-26.

Schröder JM, **Reich K,** Kabashima K, Liu FT, Romani N, Metz M, Kerstan A, Lee PHA, Loser K, Schön MP, Maurer M, Stoitzner P, Beissert S, Tokura Y, Gallo RL.

Who is really in control of skin immunity under physiological circumstances – lymphocytes, dendritic cells or keratinocytes? *Exp Dermatol.* 2006;15(11):913-29.

2005

Mössner R, **Reich K.** Infliximab: Stellenwert in der Therapie der Psoriasis. *Hautarzt.* 2005;56(9):831-8.

Mössner R, **Reich K.** Pathogenetische Aspekte der Psoriasis-Arthritis. *Haut.* 2005;(1):19-24.

Reich K, Augustin M. Biologics in der Therapie der Psoriasis. *Arzneimitteltherapie.* 2005;23(12):384-97.

Reich K, Mössner R. Enthesitis – Entzündung an den Sehnenansätzen: Mechanismus und Manifestation. *Pso Magazin.* 2005;31(3):12-3.

2003

Boehncke WH, Friedrich M, Mrowietz U, **Reich K,** Rosenbach T, Sticherling M, Thaci D. The role of biologics in the management of psoriasis: a consensus paper by the Psoriasis Study Group, Arbeitsgemeinschaft Dermatologische Forschung. *J Dtsch Dermatol Ges.* 2003;1(8):620-8.

2001

Reich K. Regulatory functions of IL-10 in the cutaneous immune system, a lesson to learn from experimental IL-10 therapy of inflammatory skin disease. *G Ital Dermatol Venereol.* 2001;136:351-70.

1992

Deusch K, **Reich K.** Immunological aspects of inflammatory bowel disease. *Endoscopy.* 1992;24(10):568-77.

Guidelines in peer reviewed journals

2011

Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, **Reich K**, Rosenbach T, Sammain A, Schlaeger M, Sebastian M, Sterry W, Streit V, Augustin M, Erdmann R, Klaus J, Koza J, Müller S, Orzechowski HD, Rosumeck S, Schmid-Ott G, Weberschock T, Rzany B. [S3-guidelines for the treatment of psoriasis vulgaris Update 2011]. *J Dtsch Dermatol Ges.* 2011;9 Suppl 2:S1-104.

Reich K, Domm S, Mrowietz U. Therapy with methotrexate in dermatology: guideline of the German Society for Dermatology. AWMF online.
<http://www.awmf.org/leitlinien/detail/ll/013-078.html> (19-Aug-2011)

Sticherling M, Augustin M, Boehncke WH, Christophers E, Domm S, Gollnick H, **Reich K**, Mrowietz U. Therapy of psoriasis in childhood and adolescence - a German expert consensus. *J Dtsch Dermatol Ges.* 2011;9(10):815-23.

Wozel G, Klein E, Mrowietz U, **Reich K**, Sebastian M, Streit V. Scalp psoriasis. *J Dtsch Dermatol Ges.* 2011;9(1):70-4.

2010

Nast A, Augustin M, Boehncke WH, Klaus J, Mrowietz U, Ockenfels HM, Philipp S, **Reich K**, Rosenbach T, Schlaeger M, Sebastian M, Sterry W, Streit V, Weisenseel P, Rzany B. Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - update: "therapeutic options" and "efalizumab". *J Dtsch Dermatol Ges.* 2010;8(1):65-6.

2009

Luger T, Reusch M, **Reich K**, Augustin M, Sterry W. Statement of the DDG and the BVDD on the EMEA recommendations regarding the use of raptiva [efalizumab]. *J Dtsch Dermatol Ges.* 2009;7(4):291-2.

Mrowietz U, Klein CE, **Reich K**, Rosenbach T, Ruzicka T, Sebastian M, Werfel T. Cyclosporine therapy in dermatology. *J Dtsch Dermatol Ges.* 2009;7(5):474-9.

Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Hönigsmann H, Hussain M, Jobling R, Karvonen SL, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne JP, Orzechowski HD, Rantanen T, **Reich K**, Reytan N, Richards H, Thio HB, van de Kerkhof P, Rzany B. European S3-guidelines on the systemic treatment of psoriasis vulgaris. *J Eur Acad Dermatol Venereol.* 2009;23 Suppl 2:1-70.

2007

Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, **Reich K**, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B; Deutsche Dermatologische Gesellschaft (DDG); Berufsverband Deutscher Dermatologen (BVDD). Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges. 2007;5 Suppl 3:1-119.

Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, **Reich K**, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B. German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res. 2007;299(3):111-38.

2006

Mrowietz U, Barth J, Boehncke WH, **Reich K**, Rosenbach T, Streit V, Wozel G. Therapy of psoriasis-arthritis and psoriasis vulgaris with infliximab. J Dtsch Dermatol Ges. 2006;4(5):444-7.

Mrowietz U, Barth J, Boehncke WH, **Reich K**, Rosenbach T, Streit V, Wozel G. Therapy of psoriasis vulgaris with efalizumab. J Dtsch Dermatol Ges. 2006;4(6):511-2.

Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, **Reich K**, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B; German Society for Dermatology. S3-Guideline for the therapy of psoriasis vulgaris. J Dtsch Dermatol Ges. 2006;4 Suppl 2:S1-S126.

Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, **Reich K**, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B. Evidenzbasierte (S3) Leitlinie zur Therapie der Psoriasis vulgaris. Der Deutsche Dermatologe. 2006;54(11):769-76.

2005

Follmann M, Sterry W, Rzany B, Boehncke WH, Weberschock T, Friedrich M, Mrowietz U, Kreiselmaier I, Ockenfels HM, Prinz J, **Reich K**, Mohr J, Rosenbach T, Schlaeger M, Sebastian M, Streit V. Development of the evidence-based guidelines

for psoriasis--a project of the German Dermatological Society (DDG). *J Dtsch Dermatol Ges.* 2005;3(9):678-89.

Letters in peer-reviewed journals

2002

Reich K, Hummel KM, Beckmann I, Mossner R, Neumann Ch. Treatment of severe psoriasis and psoriatic arthritis with leflunomide. *Br J Dermatol.* 2002;146(2):335-6.

1999

Fischer T, Schwörer H, Vente C, **Reich K**, Ramadori G. Clinical improvement of HIV-associated psoriasis parallels a reduction of HIV viral load induced by effective antiretroviral therapy. *Aids.* 1999;13(5):628-9.

1998

Reich K, Vente C, Neumann Ch. Topical tacrolimus for pyoderma gangrenosum. *Br J Dermatol.* 1998;139(4):755-7.

Reich K, Brück M, Gräfe A, Vente C, Neumann Ch, Garbe C. Treatment of psoriasis with interleukin-10. *J Invest Dermatol.* 1998;111(6):1235-6.

Original articles in non-peer reviewed journals

2011

Reich K. Alleskönner Mikroalge – neue Daten deuten auf vielfältige Einsatzmöglichkeiten als Wirkkosmetik. Kosmetische Medizin. 2011;32(2):70-73.

Reviews in non-peer reviewed journals

2010

Reich K. Spondyloarthritis from the perspective of a dermatologist. Rheumatol News Int. 2010; Suppl:9-10.

Shakery K, Reich K. Psoriasis 2010 – State of the Art. Kompendium Dermatologie. 2010;6(1):8-13.

Steinkraus V, Reich K, Breuer K. Therapy of neurodermatitis (atopic dermatitis). EADV Media InfoSheet 2010;(9):1-2.

2009

Reich K. Kurzkontakt-Therapie der Psoriasis capitis mit topischem Clobetasol-17-propionat. Kompendium Dermatologie. 2009;5(1):22-23.

Shakery K, Reich K. Nagelpsoriasis – ein Fingerzeig. ÄP Dermatologie Allergologie. 2009;(4):35-7.

Shakery K, Reich K. Psoriasis 2009 – State of the Art. Kompendium Dermatologie. 2009;5(1):2-4.

Shakery K, Reich K. Psoriasis – Krankheitsbild und aktuelle Therapie. Med Monatsschr Pharm. 2009;32(9):335-44.

2006

Reich K. Is your psoriasis patient a candidate for biologic therapy? Skin & Allergy News. 2006;Suppl:10-1.

2003

Reich K. Die Haut als Spiegel des Immunsystems. Der Dialysepatient. 2003;9:17-21.

Editorial in non-peer reviewed journal

Reich, K. Alitretinoin – ein neuer Wirkansatz für schwere chronische Handekzeme. Thieme Case Report. 2009;1(1):p1.

Books

Augustin M, **Reich K**, Radtke MA, Dierks C. Lebensqualität, Compliance und Empowerment bei Psoriasis. Bremen: UNI-MED; 2007.

Steinkraus V, **Reich K**, Schlolaut MA, Haut. Köln: DuMont; 2011

Book Chapters

2011 (accepted)

Reich K, Mrowietz U. Erythematöse, papulonodöse und erythematosquamöse Erkrankungen. In: Braun-Falco, Plewig, Burgdorf Landthaler Dermatologie und Venerologie. 6. Auflage

2010

Reich K et al. 14 Erythematöse, erythematosquamöse und pustulöse Erkrankungen. In: Dirschka, T et al., editors. Klinikleitfaden Dermatologie, 3. Auflage. München: Urban & Fischer in Elsevier; 2010. p. 561-614.

2009

Mössner R, **Reich K**. Management of severe psoriasis with TNF antagonists. Adalimumab, Etanercept and Infliximab. In: Yawalkar N, editors. Management of psoriasis (Current problems in dermatology ; 38). Basel: Karger; 2009. p. 107-136.

2006

Reich K, Schmidt G. Dermatika. In: Estler CJ, Schmidt H, editors. Pharmakologie und Toxikologie, 6th ed. Stuttgart: Schattauer; 2006. p. 943-961.

2005

Schnuch A, Uter W, **Reich K**. Allergic contact dermatitis and atopic eczema. In: Ring J, Przybilla B, Ruzicka T, editors. Handbook of atopic eczema, 2nd ed. Berlin: Springer; 2005. p. 176-99.

1991

Deusch K, Lüling F, **Reich K**, Classen M. CD8+ gamma/delta cells (TCR1+CD8+) are a major population of human intraepithelial lymphocytes. In: Tsuchiya M et al., editors. Frontiers in mucosal immunology. Excerpta Medica International Congress Series. Amsterdam: Elsevier Science; 1991. p. 145-6.

Deusch K, Pluschke G, Wagner F, Köhne G, Daum S, **Reich K**, Pfeffer K, Classen M. T-Zellrezeptorreperoire und Zytokinproduktion von humanen Darmlymphozyten. In: Seifert J et al., editors. Ökosystem Darm III. Berlin: Springer; 1991. p. 52-8.

Abstracts presented at international meetings published in peer reviewed journals

There are more than 200 abstracts published in peer reviewed journals with more than 100 listed in the ISI web of knowledge report.